Fig. 3

PSA protection from HSE is independent of induced Tregs. a % FoxP3⁺ CD4 Tregs and b CD69⁺ CD4 T cells in spleen and CLN of PSA or PBS-treated WT mice at day 6 pi. c CD25 expression within FoxP3⁺ CD4 Tregs in WT mice at day 6 pi, % and mean fluorescence intensity (MFI) in () shown in right top quadrant. d % CD25 within FoxP3⁺ Tregs (left plot) and FoxP3⁻ CD4⁺ T cells (right plot), e CD103 expression within FoxP3⁺ Tregs in WT mice at day 6 pi; % and MFI in () shown in right top quadrant. f CD103 within FoxP3⁺ Tregs (left plot) and FoxP3⁻ CD4⁺ T cells (right plot) in the spleen or CLN of WT mice at day 6 pi. Data from three experiments shown. g PSA-treated Treg depleted and control WT mice were monitored for survival after HSV infection and ACV treatment as in Fig. 1a, ns: not significant determined by log rank Mantel–Cox test (n = 11–12 mice). After administration of three (1 week) or six doses (2 weeks) of PSA, MLN in uninfected WT mice were monitored for h cellularity, i % CD4 and CD8 T cells, and j # ICOS⁺, CD39⁺, and CD73⁺ CD4 and CD8 T cells (n = 3 mice); ****p < 0.0001, **p < 0.01 as determined by two-way ANOVA or one-way ANOVA with Sidaks or Turkeys correction, respectively, for multiple comparisons tests. All data show mean ± SEM